Understanding how genetic changes affect blood disorders and fibrosis progression
Official title: Investigating High-Risk Epigenetic Modifying Alterations on JAK2VF Dependency and Fibrotic Progression in Myeloproliferative Neoplasms (MPNs)
Funded at University of Tx Md Anderson Can Ctr · NIH-11096109 · Data updated 2026-11-12
This study is looking at how certain genetic changes, especially the JAK2VF mutation, affect the progression of myeloproliferative neoplasms (MPNs) and how well treatments work, with the hope of finding better ways to help patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | June 1, 2024 |
| Project end | September 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $167,616 |
| NIH project number | 7K08HL169905-02 |
| Project ID | NIH-11096109 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms, particularly those with the JAK2VF mutation and associated genetic alterations.
✕Less likely to help
Patients without myeloproliferative neoplasms or those whose conditions are unrelated to the JAK2VF mutation may not benefit from this research.
What this research studies
This research investigates the role of specific genetic mutations in myeloproliferative neoplasms (MPNs), which are blood disorders characterized by the overproduction of blood cells and fibrosis in the bone marrow. The study focuses on the JAK2VF mutation and its interaction with other genetic alterations that may worsen the disease and hinder treatment effectiveness. By using advanced mouse models, researchers aim to uncover how these genetic changes influence disease progression and response to therapies, potentially leading to new treatment strategies for patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with myeloproliferative neoplasms by targeting the underlying genetic mechanisms of the disease.
How similar studies have gone: Previous research has shown promising results in targeting genetic mutations in blood disorders, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Dunbar, Andrew Jeffrey — University of Tx Md Anderson Can Ctr
- Study coordinator: Dunbar, Andrew Jeffrey
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.